Form 4: Eli Lilly Director Acquires Shares
Statement of Changes in Beneficial Ownership
Eli Lilly Director J. Erik Fyrwald acquired 10,036 shares of common stock on May 18, 2026, as part of a deferred compensation plan.
Summary
- J. Erik Fyrwald, a Director at Eli Lilly & Co. (LLY), acquired 10,036 shares of common stock on May 18, 2026.
- The acquisition was made at a price of $988.09 per share.
- These shares were acquired under the Lilly Directors' Deferral Plan and have been deferred as stock units.
- The shares will be settled in common stock upon Fyrwald's separation from service.
- Following this transaction, Fyrwald beneficially owns 75,279.592 shares of common stock directly.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard insider transaction for deferred compensation rather than a discretionary purchase or sale.
Positives
- Director J. Erik Fyrwald's acquisition of shares indicates continued confidence in the company.
- The acquisition is part of a structured deferral plan, suggesting a long-term commitment from management.
- The transaction involves a significant number of shares (10,036), reflecting substantial value.
Future Outlook
The acquired shares are deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
Industry Context
StockSavvy.ai notes that insider stock acquisitions, particularly by directors, are often viewed positively by the market as they signal management's belief in the company's future prospects. This aligns with typical insider behavior in the pharmaceutical sector where long-term value creation is paramount.
Stakeholder Impact
- Shareholders: The transaction reinforces management's commitment, which can be viewed positively.
- Employees: The deferral plan is part of executive compensation, indirectly impacting employee morale and retention strategies.
- Management: J. Erik Fyrwald's continued investment in the company's stock.
Next Steps
- Settlement of deferred stock units in common stock upon J. Erik Fyrwald's separation from service.
Key Dates
| Date | Description |
|---|---|
| 05/18/2026 | Transaction Date for acquisition of common stock by J. Erik Fyrwald. |
| 05/19/2026 | Date of signature for the filing. |
Keywords
Eli Lilly, LLY, Form 4, Insider Trading, Director, Stock Acquisition, Deferred Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.